Moneycontrol PRO
HomeNewsBusinessStocksGlaxoSmithKline Pharmaceuticals share price falls 2.04%; stock among top losers on Nifty Midcap 150

GlaxoSmithKline Pharmaceuticals share price falls 2.04%; stock among top losers on Nifty Midcap 150

The stock is a constituent of the Nifty Midcap 150 index.

September 12, 2025 / 11:07 IST
Disclaimer This is an AI-assisted live blog with updates from multiple sources Disclaimer
     
     
    26 Aug, 2025 12:21
    Volume
    Todays L/H
    More

    Shares of GlaxoSmithKline Pharmaceuticals declined 2.04% to Rs 2,805.30 in Friday's session, making it among the top losers on the Nifty Midcap 150. At 10:46 am, the stock experienced this downturn.

    Financial Overview

    The following tables provide an overview of GlaxoSmithKline Pharmaceuticals' financial performance, including quarterly and annual consolidated results.

    Consolidated Quarterly Results

    HeadingJun 2024Sep 2024Dec 2024Mar 2025Jun 2025
    RevenueRs 814.65 CroreRs 1,010.77 CroreRs 949.42 CroreRs 974.37 CroreRs 805.17 Crore
    Net ProfitRs 182.33 CroreRs 252.50 CroreRs 229.88 CroreRs 262.87 CroreRs 205.01 Crore
    EPS10.7614.9113.5715.5212.10

    The revenue for the quarter-ending September 2024 was Rs 1,010.77 Crore, which then decreased to Rs 974.37 Crore for the quarter-ending March 2025. The net profit saw a similar trend, peaking at Rs 262.87 Crore in March 2025. The revenue decreased by 1.16% from Rs 814.65 crore in June 2024 to Rs 805.17 crore in June 2025. The net profit increased by 12.4% from Rs 182.33 crore in June 2024 to Rs 205.01 crore in June 2025.

    Consolidated Yearly Results

    Heading20212022202320242025
    RevenueRs 2,925.60 CroreRs 3,278.03 CroreRs 3,251.72 CroreRs 3,453.71 CroreRs 3,749.21 Crore
    Net ProfitRs 287.27 CroreRs 380.77 CroreRs 607.64 CroreRs 589.96 CroreRs 927.58 Crore
    EPS31.3599.2936.0841.1454.52
    BVPS87.26157.19102.79104.93115.19
    ROE24.2263.6435.4133.4247.67
    Debt to Equity0.000.000.000.000.00

    The annual revenue has shown steady growth, increasing from Rs 2,925.60 Crore in 2021 to Rs 3,749.21 Crore in 2025. Net profit has also increased significantly from Rs 287.27 Crore in 2021 to Rs 927.58 Crore in 2025. The company’s debt to equity ratio has remained at zero for the past five years.

    Key Financial Ratios (Year-Ending March 2025)

    RatioValue (Mar 2025)Value (Mar 2024)Value (Mar 2023)Value (Mar 2022)Value (Mar 2021)
    P/E (x)52.8347.3236.7216.7945.96
    P/B (x)24.9818.5212.8810.5816.51
    EV/EBITDA (x)35.7730.8923.5130.6732.80
    P/S (x)13.009.536.908.598.34
    Basic EPS (Rs.)54.5241.1436.0899.2931.35
    Diluted Eps (Rs.)54.7634.8336.05100.0421.14
    Corporate Actions

    GlaxoSmithKline Pharmaceuticals announced a final dividend of Rs 42 per share on May 13, 2025, with an effective date of May 30, 2025. Earlier, the company had declared bonus issues, with the latest one on July 24, 2018, in the ratio of 1:1, exbonus date being September 11, 2018.

    The stock is a constituent of the Nifty Midcap 150 index.

    Alpha Desk
    first published: Sep 12, 2025 11:07 am

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347